What is B. Riley's Forecast for KYMR FY2025 Earnings?

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at B. Riley issued their FY2025 earnings per share estimates for shares of Kymera Therapeutics in a research note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel expects that the company will earn ($3.95) per share for the year. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics' FY2026 earnings at ($4.46) EPS, FY2027 earnings at ($5.62) EPS and FY2028 earnings at ($5.82) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million.

A number of other analysts also recently weighed in on KYMR. Wells Fargo & Company upgraded Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $38.00 to $57.00 in a report on Monday, December 2nd. BMO Capital Markets assumed coverage on Kymera Therapeutics in a report on Friday, December 6th. They issued a "market perform" rating and a $55.00 price objective for the company. Stephens restated an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. BTIG Research began coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They issued a "buy" rating and a $60.00 price objective for the company. Finally, HC Wainwright increased their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $56.69.

Remove Ads

Kymera Therapeutics Price Performance

NASDAQ KYMR traded up $0.35 on Wednesday, reaching $32.89. The company had a trading volume of 639,628 shares, compared to its average volume of 584,001. The firm has a market cap of $2.14 billion, a price-to-earnings ratio of -14.06 and a beta of 2.22. Kymera Therapeutics has a fifty-two week low of $29.07 and a fifty-two week high of $53.27. The business has a 50 day moving average of $38.09 and a two-hundred day moving average of $43.30.

Insider Activity

In other news, insider Ellen Chiniara sold 3,129 shares of the firm's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares in the company, valued at $2,288,985.50. This trade represents a 5.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares of the company's stock, valued at approximately $2,064,510. This represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 13,788 shares of company stock worth $455,202 in the last three months. Company insiders own 15.82% of the company's stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several large investors have recently added to or reduced their stakes in KYMR. Blue Trust Inc. lifted its position in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after acquiring an additional 270 shares in the last quarter. State of Wyoming bought a new position in Kymera Therapeutics in the 4th quarter valued at about $45,000. GF Fund Management CO. LTD. bought a new position in Kymera Therapeutics in the 4th quarter valued at about $55,000. KBC Group NV lifted its position in Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after acquiring an additional 752 shares in the last quarter. Finally, Quarry LP bought a new position in shares of Kymera Therapeutics during the 3rd quarter worth approximately $95,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.